SWOG clinical trial number
CTSU/A021804

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Open
Phase
Abbreviated Title
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
Status Notes
Charles D. Lopez, M.D., Ph.D. SWOG Champion.
Activated
11/02/2020

Research committees

Gastrointestinal Cancer

Treatment

Temozolomide Olaparib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2023

A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

J Del Rivero;K Perez;S Geyer;M Khalil;A Vijendran;A Kordaris-Corkill;A Shegrill;H Soares;C Lopez;A Nixon;A Dueck;J Meyerhardt;E O'Reilly J Clin Oncol 41, 2023 (suppl 16; abstr TPS4191); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster